Latest market price
121.27
+1.63+1.36%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.86 | Insider Own | 3.98% | Shs Outstand | 32.96M | Perf Week | 11.61% |
| Market Cap | 4.00B | Forward P/E | 107.48 | EPS next Y | 1.13 | Insider Trans | -4.81% | Shs Float | 30.29M | Perf Month | 9.45% |
| Enterprise Value | 4.12B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 10.02% | Perf Quarter | 8.13% |
| Income | -27.00M | P/S | 5.07 | EPS this Y | - | Inst Trans | - | Short Ratio | 5.18 | Perf Half Y | -0.88% |
| Sales | 788.00M | P/B | 21.49 | EPS next Y | - | ROA | -1.28% | Short Interest | 3.03M | Perf YTD | -31.66% |
| Book/sh | 5.64 | P/C | 6.76 | EPS next 5Y | - | ROE | -8.97% | 52W High | 212.01 -42.80% | Perf Year | -31.44% |
| Cash/sh | 17.93 | P/FCF | 102.56 | EPS past 3/5Y | - | ROIC | -1.05% | 52W Low | 100.70 20.43% | Perf 3Y | 44.64% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 22.04% 23.03% | Gross Margin | 71.45% | Volatility | 4.02% 3.55% | Perf 5Y | 67.75% |
| Dividend TTM | - | EV/Sales | 5.23 | EPS Y/Y TTM | 76.31% | Oper. Margin | -1.17% | ATR (14) | 4.29 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.75 | Sales Y/Y TTM | 33.11% | Profit Margin | -1.69% | RSI (14) | 66.67 | Recom | 2.14 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.87 | EPS Q/Q | 97.73% | SMA20 | 9.80% | Beta | 1.38 | Target Price | 173.22 |
| Payout | 0.00% | Debt/Eq | 4.67 | Sales Q/Q | 19.79% | SMA50 | 5.59% | Rel Volume | 0.79 | Prev Close | 119.64 |
| Employees | 2,400 | LT Debt/Eq | 4.67 | Earnings | Nov 05 | SMA200 | -1.85% | Avg Volume | 575.07K | Price | 121.27 |
| IPO Date | Oct 20, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 75.00% 2.22% | Net Debt/EBITDA | 17.90 | Volume | 456,651 | Change | 1.36% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-16-26 | Initiated | Piper Sandler | Overweight | $160 |
| Aug-18-26 | Reiterated | Wells Fargo | Overweight | $225 → $168 |
| Aug-10-26 | Reiterated | Truist Securities | Buy | $160 → $168 |
| Aug-07-26 | Reiterated | Robert W. Baird | $160 → $165 | |
| Aug-07-26 | Reiterated | Canaccord Genuity | Buy | $157 → $196 |
| Aug-07-26 | Reiterated | Needham | Buy | $255 → $192 |
| Aug-07-26 | Reiterated | Evercore ISI Group | Outperform | $150 → $165 |
| Jul-22-26 | Initiated | Stephens | Overweight | $160 |
| Jul-16-26 | Reiterated | Truist Securities | Buy | $174 → $160 |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $160 → $150 |
Latest News· Times ET
Oct-19-26
Oct-18-26
Oct-18-2604:32AM
Oct-15-26
Oct-15-2604:05PM
Oct-13-26
Oct-13-2603:19PM
Oct-10-26
Oct-06-26
Oct-06-2607:59PM
07:02AM
Oct-05-26
Oct-05-2609:05AM
Oct-02-26
Oct-02-2604:41PM
Sep-27-26
Sep-27-2610:56AM
Sep-23-26
Sep-22-26
Sep-15-26
Company
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 788 | 747 | 592 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 229 | 220 | 184 | — | — | — | — | — | — | |
| Gross Profit | 559 | 527 | 408 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 500 | 479 | 419 | — | — | — | — | — | — | |
| Research and Development | 84 | 85 | 104 | — | — | — | — | — | — | |
| Other Operating Expense | -4 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -22 | -37 | -116 | — | — | — | — | — | — | |
| Interest Expense | 12 | 13 | 13 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 6 | 16 | — | — | — | — | — | — | |
| Net Income Before Taxes | -26 | -44 | -113 | — | — | — | — | — | — | |
| Income Taxes | 1 | 1 | 1 | — | — | — | — | — | — | |
| Consolidated Net Income | -27 | -45 | -113 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -27 | -45 | -113 | — | — | — | — | — | — | |
| Net Income | -27 | -45 | -113 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.86 | -1.39 | -3.63 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.86 | -1.39 | -3.63 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.86 | -1.39 | -3.63 | — | — | — | — | — | — | |
| EBITDA | 12 | -4 | -74 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.08 | 7.60 | 4.72 | — | — | — | — | — | — | |
| Gross Margin | 70.94 | 70.55 | 68.92 | — | — | — | — | — | — | |
| Operating Margin | -2.79 | -4.95 | -19.59 | — | — | — | — | — | — | |
| Net Margin | -3.43 | -6.02 | -19.09 | — | — | — | — | — | — | |
| Shares Outstanding | 33 | 32 | 31 | — | — | — | — | — | — | |
| Market Capitalization | 4,002 | 5,678 | 2,795 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Wilson Daniel G. | Chief Financial Officer | Sep 02 '26 | Sale | 121.83 | 773 | 94,175 | 34,887 | Sep 03 |
| Blackford Quentin S. | President and CEO | Aug 10 '26 | Sale | 124.65 | 26,859 | 3,348,012 | 226,008 | Aug 11 |
| Shrishrimal Sumi | EVP, Chief Risk Officer | Aug 10 '26 | Sale | 124.65 | 5,372 | 669,641 | 44,621 | Aug 11 |
| Murphy Patrick Michael | CBO and CLO | Aug 10 '26 | Sale | 124.65 | 7,093 | 884,156 | 69,699 | Aug 11 |
| Turakhia Minang | CHIEF MED/SCI OFCR EVP ADVTECH | Aug 10 '26 | Sale | 124.65 | 7,093 | 884,151 | 60,116 | Aug 11 |
| Patterson Chad | CHIEF COMM & PRODUCT OFFICER | Aug 10 '26 | Sale | 124.65 | 7,093 | 884,170 | 62,125 | Aug 11 |
| Smith Mervin | EVP Strategic Business Ops | Aug 03 '26 | Sale | 122.12 | 617 | 75,349 | 22,410 | Aug 04 |
| Rodda Julianne | EVP, CHIEF PEOPLE OFFICER | Aug 03 '26 | Sale | 122.12 | 2,112 | 257,919 | 18,201 | Aug 04 |
| Patterson Chad | CHIEF COMM & PRODUCT OFFICER | Aug 03 '26 | Sale | 122.12 | 2,712 | 331,192 | 55,629 | Aug 04 |
| Turakhia Minang | CHIEF MED/SCI OFCR EVP ADVTECH | Jul 02 '26 | Sale | 124.71 | 1,423 | 177,462 | 53,620 | Jul 06 |
| Freeman Sean Clinton | EVP, Strategy & Corp Devt | Jul 02 '26 | Sale | 124.71 | 918 | 114,484 | 13,641 | Jul 06 |
| TALWALKAR ABHIJIT Y | Director | May 11 '26 | Buy | 10.71 | 5,312 | 56,892 | 25,611 | May 12 |
| TALWALKAR ABHIJIT Y | Director | May 11 '26 | Sale | 117.93 | 5,312 | 626,430 | 20,299 | May 12 |
| TALWALKAR ABHIJIT Y | Director | May 11 '26 | Option Exercise | 10.71 | 5,312 | 56,892 | 0 | May 12 |
| Lawrence Brian Lee | Chief Technology Officer | May 04 '26 | Sale | 120.80 | 1,014 | 122,491 | 20,154 | May 05 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.